A Monotherapy in Subjects With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Solid Tumor, Adult
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: The starting dose in this dose-escalation study is 25 mg, and the preset 7 dose-escalation cohorts are 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Subjects with advanced solid tumors who have no available standard therapy or who have failed standard therapies. This is an open-label, global multicenter, dose-escalation phase 1 study of safety, tolerability, preliminary PK profile, and preliminary efficacy of 3D185 monotherapy in subjects with a...
Subjects with advanced solid tumors who have no available standard therapy or who have failed standard therapies. This is an open-label, global multicenter, dose-escalation phase 1 study of safety, tolerability, preliminary PK profile, and preliminary efficacy of 3D185 monotherapy in subjects with advanced solid tumors. The starting dose in this dose-escalation study is 25 mg, and the preset 7 dose-escalation cohorts are 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively.
Tracking Information
- NCT #
- NCT04221204
- Collaborators
- Not Provided
- Investigators
- Study Director: Sixing Kan 3D Medicines (Beijing) Co., Ltd.